Article ID Journal Published Year Pages File Type
9601065 Clinical Oncology 2005 7 Pages PDF
Abstract
The treatment of PCNSL is associated with significant early and late toxicity. Further attempts to improve treatment should address mechanisms to reduce this toxicity. In particular, the benefit of radiotherapy in patients who achieve complete remission with HDMTX will remain uncertain until it is addressed in a multicentre, randomised trial.
Related Topics
Health Sciences Medicine and Dentistry Oncology
Authors
, , , , , , , , , ,